PCN48 - REAL-WORLD TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

Abstract

The objective of this study was to describe number, type and duration of systemic treatment lines (STLs) of patients with advanced non-small cell lung cancer (aNSCLC). aNSCLC patients observable for at least 12 months from their incident diagnosis were identified in a German claims dataset, covering the years 2011-2017. First prescription after diagnosis was defined as a start of treatment. To identify mutation positive patients as a subgroup, reimbursement codes for genetic testing followed by targeted treatment were used. All agents prescribed within 21 days after starting a STL were considered combination therapy. Start of a new STL was defined as date of any prescription of an agent which was not prescribed within the preceding STL. End of a STL was assumed when a new STL was initiated, or there was no further prescription of the agent(s) of the respective previous STL for at least 90 days. 1,741 patients were included in this analysis (mean age: 66.97 years, female: 29.87%). Based on a 12 month follow up, 5.34% of patients received no systemic treatment, 68.81% received one STL only, 19.47% received two STLs, 5.17% received three STLs, and 1.21% received >3 STLs. In 122 patients who were considered mutation positive, the respective numbers were 6.56%/37.70%/38.52%/13.93%/ 3.28%. For patients who were observable for 24 months, the respective numbers were 4.54%/60.29%/22.40%/8.79%/3.98% (mutation positive: 3.77%/16.98%/36.79%/24.53%/17.92%). Most often prescribed first-STL-treatments (% patients) were: pemetrexed (28.95%) and pemetrexed-bevacizumab (7.36%). As second-STL, Erlotinib (25.83%) was the most often prescribed treatment. Mean duration of 1/2/3-STL treatment was 229.28/225.09/190.78 days (mutation positive: 228.82/236.75/186.23). It is known that overall survival of aNSCLC patients is strongly associated with number of STLs. There is a high unmet need in the real-world treatment of aNSCLC patients, as only one quarter receives more than one STL.